As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma
Published in: European Journal of Cancer
BACKGROUND: Patients with limited-stage primary testicular lymphoma (PTL) typically receive a multimodal regimen, including 6 cycles of R-CHOP, despite limited evidence. In low-risk diffuse large B-cell lymphoma, de-escalation to 4 R-CHOP cycles has proven non-inferior. It remains unclear whether similar de-escalation is feasible in PTL. METHODS: Patients aged ≥ 18 years with Ann Arbor stage I-II PTL diagnosed between 2014 and 2021 were identified in the Netherlands Cancer Registry. Patients receiving ≥ 3 R-CHOP cycles were included. Outcomes were 5-year progression-free survival (PFS), overall survival (OS), and cumulative incidence function...
Diana Al-Sarayfi,
Johanna A A Bult, Ruben A L de Groen, Fleur A de Groot, Joost S P Vermaat, Djamilla Issa,
Arjan Diepstra,
Gerwin Huls,
Mar Bellido,
Wouter Plattel,
Mirian Brink,
Marcel Nijland
Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin Lymphoma
Published in: Blood Advances
Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives
Published in: Leukemia & lymphoma
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of 15 different neoplasms in adults. In Europe and North America, PTCL not otherwise specified (PTCL NOS), nodal T follicular helper lymphoma, angioimmunoblastic type (nTFHL-AI), and anaplastic large cell lymphoma (ALCL) either anaplastic lymphoma kinase (ALK) positive (+) or negative (-) are the most prevalent PTCLs. Relapsed or refractory disease (R/R) is common in PTCL and its management is challenging. Despite response rates and prognoses being disease specific, the outcome of R/R PTCL is dismal except for R/R ALK+ ALCL....
Serum TARC dynamics during anti-PD1-based first-line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial
Published in: HemaSphere
Wouter J Plattel,
Sophie Teesink,
Lydia Visser, Conrad-Amadeus Voltin, Helen Kaul, Hans A Schlößer,
Bart-Jan Kroesen, Carsten Kobe, Bastian von Tresckow, Peter Borchmann,
Arjan Diepstra, Paul J Bröckelmann
Working towards harmonization of clinical trial reporting in Hodgkin lymphoma
Published in: HemaSphere
Carsten Kobe, Philippe Armand, Sven Borchmann, Graham P Collins, Anne-Segolene Cottereau, Justin Ferdinandus, Alex F Herrera, Davide Rossi,
Wouter J Plattel, Sally F Barrington, Martin Hutchings
